Wyeth and its new parent Pfizer are probably wishing they had more to be thankful for this week, after being hit with jury awards totaling more than $100 million over hormone drugs. But what started out as a tough week for Big Pharma got a little better late Monday, when Manhattan federal Judge John Keenan dismissed the second of three bellwether cases facing Merck over its osteoporosis drug Fosamax just weeks before it was set for trial.
Merck Knocks Out Second Fosamax Test Case Before Trial
The American Lawyer
November 25, 2009